Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
This study has been terminated.
Study NCT00080002   Information provided by Enzon Pharmaceuticals, Inc.
First Received: March 19, 2004   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer of Stomach
Gastroesophageal Cancer
Additional conditions recognized in this trial
Neoplasm Metastasis
Stomach Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Stomach Diseases
Interventions listed in this trial
Pegamotecan
Additional drug interventions recognized in this trial
Camptothecin
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Enzon Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services